Cipla’s Revlimid Settlement Offers Date-Certain US Launch

Deal With Bristol Myers Squibb's Celgene Allows Initial ‘Limited’ Volumes

 
• By Dave Wallace

Cipla has become the latest generics firm to settle US patent litigation with Bristol Myers Squibb’s Celgene over its Revlimid blockbuster.

Handshake
Cipla and Bristol Myers Squibb's Celgene have settled over Revlimid • Source: Shutterstock

More from Deals

More from Business